keyword
MENU ▼
Read by QxMD icon Read
search

Novartis

keyword
https://www.readbyqxmd.com/read/27890073/switching-to-nilotinib-versus-imatinib-dose-escalation-in-patients-with-chronic-myeloid-leukaemia-in-chronic-phase-with-suboptimal-response-to-imatinib-lasor-a-randomised-open-label-trial
#1
Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, Jose Luis Lopez, Eduardo Bullorsky, Sandip Shah, Xiaojun Huang, K Govind Babu, Kudrat Abdulkadyrov, José Salvador Rodrigues de Oliveira, Zhi-Xiang Shen, Tomasz Sacha, Israel Bendit, Zhizhou Liang, Tina Owugah, Tomasz Szczudlo, Sadhvi Khanna, Rafik Fellague-Chebra, Philipp D le Coutre
BACKGROUND: Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response remains undetermined. This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib dose escalation for patients with suboptimal cytogenetic response on imatinib. METHODS: We did a phase 3, open-label, randomised trial in patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response to imatinib according to the 2009 European LeukemiaNet criteria, in Latin America, Europe, and Asia (59 hospitals and care centres in 12 countries)...
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27888177/study-protocol-for-a-cluster-randomised-controlled-trial-of-an-ncd-access-to-medicines-initiative-evaluation-of-novartis-access-in-kenya
#2
Peter C Rockers, Veronika J Wirtz, Taryn Vian, Monica A Onyango, Paul G Ashigbie, Richard Laing
INTRODUCTION: Novartis recently launched Novartis Access, an initiative to provide a basket of reduced price medicines for non-communicable diseases (NCDs) to be sold through the public and private non-profit sectors in programme countries. This study will evaluate the impact of Novartis Access on the availability and price of NCD medicines at health facilities and households in Kenya, the first country to receive the programme. METHODS AND ANALYSIS: This study will be a cluster-randomised controlled trial...
November 25, 2016: BMJ Open
https://www.readbyqxmd.com/read/27882888/comparison-of-two-freely-available-software-packages-for-mass-spectrometry-imaging-data-analysis-using-brains-from-morphine-addicted-rats
#3
Anna Bodzon-Kulakowska, Marta Marszalek-Grabska, Anna Antolak, Anna Drabik, Jolanta H Kotlinska, Piotr Suder
Data analysis from mass spectrometry imaging (MSI) imaging experiments is a very complex task. Most of the software packages devoted to this purpose are designed by the mass spectrometer manufacturers and, thus, are not freely available. Laboratories developing their own MS-imaging sources usually do not have access to the commercial software, and they must rely on the freely available programs. The most recognized ones are BioMap, developed by Novartis under Interactive Data Language (IDL), and Datacube, developed by the Dutch Foundation for Fundamental Research of Matter (FOM-Amolf)...
2016: European Journal of Mass Spectrometry
https://www.readbyqxmd.com/read/27882837/determining-multiple-sclerosis-phenotype-from-electronic-medical-records
#4
Richard E Nelson, Jorie Butler, Joanne LaFleur, Kristin Knippenberg, Aaron W C Kamauu, Scott L DuVall
BACKGROUND: Multiple sclerosis (MS), a central nervous system disease in which nerve signals are disrupted by scarring and demyelination, is classified into phenotypes depending on the patterns of cognitive or physical impairment progression: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), or progressive-relapsing MS (PRMS). The phenotype is important in managing the disease and determining appropriate treatment. The ICD-9-CM code 340.0 is uninformative about MS phenotype, which increases the difficulty of studying the effects of phenotype on disease...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27875522/hedgehog-inhibition-enhances-efficacy-of-radiation-and-cisplatin-in-orthotopic-cervical-cancer-xenografts
#5
Naz Chaudary, Melania Pintilie, David Hedley, Richard P Hill, Michael Milosevic, Helen Mackay
BACKGROUND: The Hedgehog (Hh) pathway is upregulated in cervical cancer and associated with poor outcome. We explored the effects of Hh pathway inhibition in combination with RTCT in a patient derived orthotopic cervical cancer xenograft model (OCICx). METHODS: 5E1, a monoclonal antibody for SHH, or Sonidegib (LDE225), a clinical SMO inhibitor (Novartis) were added to RTCT. We investigated tumour growth delay, metastasis and GI toxicity using orthotopic cervical cancer xenografts models...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27864013/factors-predictive-of-response-disease-progression-and-overall-survival-after-dabrafenib-and-trametinib-combination-treatment-a-pooled-analysis-of-individual-patient-data-from-randomised-trials
#6
Georgina V Long, Jean-Jacques Grob, Paul Nathan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Stephen R Lane, Carmen Mak, Philippe Legenne, Keith T Flaherty, Michael A Davies
BACKGROUND: Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAF(V600E)-mutant or BRAF(V600K)-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of patient management. We aimed to identify clinical factors associated with long-term response and survival using pooled data from randomised trials of dabrafenib plus trametinib in patients with metastatic BRAF-mutant melanoma...
November 15, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27845825/withdrawn-oxcarbazepine-add-on-for-drug-resistant-partial-epilepsy
#7
REVIEW
Sergio M Castillo, Dieter B Schmidt, Sarah White, Arif Shukralla
BACKGROUND: Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the effects of oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy...
November 15, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27843120/bortezomib-thalidomide-dexamethasone-and-panobinostat-for-patients-with-relapsed-multiple-myeloma-muk-six-a-multicentre-open-label-phase-1-2-trial
#8
Rakesh Popat, Sarah R Brown, Louise Flanagan, Andrew Hall, Walter Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh
BACKGROUND: Panobinostat (a pan histone deacetylase inhibitor) is approved in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma who have received two or more previous lines of therapy. We aimed to improve the safety of this combination and investigate efficacy by incorporating low-dose thalidomide, using sub-cutaneous weekly bortezomib, and determining the maximum tolerated dose of panobinostat in this regimen. METHODS: We did a phase 1/2, multicentre, open-label trial (MUK six) at four hospitals in the UK, enrolling patients with relapsed, or relapsed and refractory, multiple myeloma aged at least 18 years, with an Eastern Cooperative Oncology Group performance status of 2 or less who had previously received 1-4 lines of therapy...
November 11, 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27824842/car-t-cells-forge-ahead-novartis-reorganizes
#9
Cormac Sheridan
No abstract text is available yet for this article.
November 8, 2016: Nature Biotechnology
https://www.readbyqxmd.com/read/27819760/reversible-cerebral-vasoconstriction-syndrome-in-association-with-fingolimod-use
#10
Scott Belliston, Jayshree Sundararajan, Kathy Newell, Sharon Lynch
BACKGROUND: Reversible cerebral vasoconstriction syndrome (RCVS), also known as Call-Fleming syndrome, is characterized by thunderclap headaches, non-aneurysmal segmental cerebral vasoconstriction seen on arteriogram, and spontaneously resolves within twelve weeks. Fingolimod has been reported to cause posterior reversible encephalopathy syndrome (PRES) and one case of RCVS. OBJECTIVE: We report a case of RCVS possibly related to fingolimod use, and compare to cases of adverse outcomes in fingolimod use...
November 7, 2016: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27801641/a-systematic-review-and-economic-evaluation-of-bisphosphonates-for-the-prevention-of-fragility-fractures
#11
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby, Neil Gittoes
BACKGROUND: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax(®) and Fosamax(®) Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel(®) and Actonel Once a Week(®), Warner Chilcott UK Ltd), ibandronic acid (Bonviva(®), Roche Products Ltd) and zoledronic acid (Aclasta(®), Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their cost-effectiveness at varying levels of fracture risk...
October 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27801315/-efficacy-and-safety-of-jak-inhibitor-ruxolitinib-in-chinese-patients-with-myelofibrosis-results-of-a-1-year-follow-up-of-a2202
#12
J Jin, X Du, D B Zhou, J M Li, J Y Li, M Hou, T Liu, D P Wu, Y Hu, Z J Xiao
Objective: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. Methods: This study enrolled 63 Chinese patients(32 males and 31 females)in total, whose median age was 55(25-79)years. The initial dose of ruxolitinib was 30mg/d(25 patients)with a baseline of PLT(100-200)×10(9)/L and 40 mg/d(38 patients)with a baseline of PLT>200×10(9)/L. Spleen volume, quality of life(QOL)and symptoms were evaluated by MRI/CT, European Organization for Research and Treatment of Cancer QOL Questionnaire Core 30(EORTC QLQ-C30)and MF Symptom Assessment Form(MFSAF)v2...
October 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27786583/the-efficacy-and-safety-profile-of-ocriplasmin-in-vitreomacular-interface-disorders
#13
Mehrine Shaikh, John B Miller, Thanos D Papakostas, Deeba Husain
Vitreomacular adhesion (VMA) describes the adhesion of the posterior hyaloid face to the inner retina in any part of the macula. This can arise after incomplete separation of the posterior vitreous cortex from the macula during vitreous liquefaction. While the VMA may resolve spontaneously, a strong and persistent adhesion can lead to a variety of anatomical changes, including vitreomacular traction (VMT) and macular hole (MH). Both conditions can present with metamorphopsia and decreased vision. In cases of symptomatic VMT and full-thickness macular hole, pars plana vitrectomy has long been the standard of care...
October 27, 2016: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/27771803/efficacy-against-nematode-infections-and-safety-of-afoxolaner-plus-milbemycin-oxime-chewable-tablets-in-domestic-dogs-under-field-conditions-in-europe
#14
Steffen Rehbein, Martin Knaus, Yasmina Mallouk, Tatjana Breiltgens, Emanuele Brianti, Balázs Capári, Filipe Dantas-Torres, Michel Gau, Anja Joachim, Karl-Heinz Kaulfuß, Zvezdelina Kirkova, Joerg Lechner, Andrei D Mihalca, Rosamaria Mirabito, Saulius Petkevičius, Dhimitër Rapti, Enstela Shukullari, Michel Sedeilhan, Doris Dollhofer, Katrin Kley, Wilfried Lebon, Martin Visser, Philippe Jeannin
Afoxolaner (AFX) plus milbemycin oxime (MO) combination chewable tablets (NexGard Spectra®, Merial) were evaluated for safety and efficacy against naturally acquired nematode infections in domestic dogs in a multi-centre, positive control, blinded field study using a randomized block design based on the order of presentation for allocation. In total, 408 dogs confirmed positive for naturally acquired infections of intestinal nematodes by pre-treatment faecal examination were studied in ten countries in Europe (Albania, Austria, Bulgaria, France, Germany, Hungary, Italy, Lithuania, Romania and Slovakia)...
October 22, 2016: Parasitology Research
https://www.readbyqxmd.com/read/27762554/the-performance-of-dark-chemical-matter-in-high-throughput-screening
#15
Ingo Muegge, Prasenjit Mukherjee
A statistical analysis of 203 high-throughput screens was conducted studying the propensity of small molecules in the Boehringer Ingelheim screening deck to show biological activity after having tested inactive previously in a growing number of screening assays. Dark chemical matter (DCM) compounds, which have been tested and found inactive in 50 or more assays, exhibit hit rates that are comparable to those of compounds tested in much fewer assays. Only compounds tested inactive in 125 or more assays start showing a hit rate deterioration of up to 40% compared to compounds tested in less than 25 assays...
October 20, 2016: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/27751707/overall-survival-of-patients-with-relapsed-multiple-myeloma-treated-with-panobinostat-or-placebo-plus-bortezomib-and-dexamethasone-the-panorama-1-trial-a-randomised-placebo-controlled-phase-3-trial
#16
Jesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A Dimopoulos, Ashraf Elghandour, Wieslaw W Jedrzejczak, Andreas Günther, Thanyaphong N Nakorn, Noppadol Siritanaratkul, Robert L Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae H Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Florence Binlich, Paul G Richardson
BACKGROUND: Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus bortezomib and dexamethasone in the phase 3 PANORAMA 1 trial. Here, we present the final overall survival analysis for this trial. METHODS: PANORAMA 1 is a randomised, placebo-controlled, double-blind, phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma with one to three previous treatments...
October 14, 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27747518/secukinumab-a-new-treatment-option-for-psoriatic-arthritis
#17
Philip Mease, Iain B McInnes
INTRODUCTION: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27717303/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer
#18
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Shani Paluch-Shimon, Mario Campone, Kimberly L Blackwell, Fabrice André, Eric P Winer, Wolfgang Janni, Sunil Verma, Pierfranco Conte, Carlos L Arteaga, David A Cameron, Katarina Petrakova, Lowell L Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva-Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne M Favret, Denise Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle Miller, Caroline Germa, Samit Hirawat, Joyce O'Shaughnessy
Background The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). Methods In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease...
November 3, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27703782/ketamine-stimulating-antidepressant-treatment
#19
Gin S Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A Frye, Michael Gitlin, Sidney H Kennedy, Terence A Ketter, Raymond W Lam, Rupert McShane, Alex J Mitchell, Michael J Ostacher, Sakina J Rizvi, Michael E Thase, Mauricio Tohen
SUMMARY: The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations...
May 2016: BJPsych Open
https://www.readbyqxmd.com/read/27703769/testing-the-social-competition-hypothesis-of-depression-using-a-simple-economic-game
#20
Aleksandra Kupferberg, Oliver M Hager, Urs Fischbacher, Laura S Brändle, Melanie Haynes, Gregor Hasler
BACKGROUND: Price's social competition hypothesis interprets the depressive state as an unconscious, involuntary losing strategy, which enables individuals to yield and accept defeat in competitive situations. AIMS: We investigated whether patients who suffer from major depressive disorder (MDD) would avoid competition more often than either patients suffering from borderline personality disorder (BPD) or healthy controls. METHOD: In a simple paper-folding task healthy participants and patiens with MDD and BPD were matched with two opponents, one with an unknown diagnosis and one who shared their clinical diagnosis, and they had to choose either a competitive or cooperative payment scheme for task completion...
March 2016: BJPsych Open
keyword
keyword
49741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"